Latest Conference Articles

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Addressing the external factors that can have an impact on patient health can make clinical interventions more effective when administered.

The tools that can be used to reduce health disparities exist, but they must be widely disseminated to populations across the US.

Pharmacists can fill a role for patients, but without technology supporting workflows and reimbursement efforts, challenges will remain.

Through Surescripts, pharmacists can cut down on back-and-forth with prescribers’ offices, saving valuable time for patient care.

Pharmacists must be able to view clinical information about patients in order to provide the best clinical care.

However, reimbursement for these services for pharmacists remains a crucial issue.

Inviting members of Congress into the pharmacy helps legislators experience first hand the value that pharmacists bring to their communities.

Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.

A collaboration with Blue Cross and Blue Shield of North Carolina focused on commercial populations has improved care and lowered costs in the state.

Both the restructuring of direct and indirect remuneration fees and health care cyber attacks made an impact on the industry in the first half of 2024.

Perhaps unsurprisingly, GLP-1 therapies are expected to continue making headlines within the industry.

To scale up diabetes intervention programs, sustainable workflows, trainings, and payment models are key.